The FAST Board of Directors announces that John Schlueter has been named to serve as interim Chairperson of the Board, with Bryan Thompson and Kelly David serving as Co-Vice Chairs. This leadership change enables our former Board Chairperson and founding member, Paula Evans, to focus attention on her vital work as CEO of GeneTx Biotherapeutics, LLC.
As the founder of FAST, Paula led the Foundation’s global growth and development. Through her vision and tenacity, she helped launch and grow this organization and build a strong donor network to support our single mission: to cure Angelman syndrome.
Paula also played a key role in the 2017 launch of FAST’s for-profit subsidiary, GeneTx Biotherapeutics, LLC, for which she serves as CEO. Paula’s entrepreneurial spirit has helped the company bring the first potentially disease modifying therapeutic, GTX-102, an antisense oligonucleotide, into a phase 1/2 clinical trial. The FAST board is proud to support Paula and the GeneTx team in this vital work.
FAST is committed to funding and aggressively pursuing the critical research needed to progress meaningful therapeutics for those living with Angelman syndrome. We are eternally grateful to Paula for her vision and dedication to our community, and we will not stop until this mission is accomplished.
If you have any questions, please reach out to email@example.com.
FAST Board of Directors